BioSpace News Archive

Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief Executive Officer for Marizyme.

SCIEX, a global leader in life science analytical technologies, and RedShiftBio®, a provider of next-generation platform technology enabling measurements of previously undetectable structure changes in biomolecules, have entered into a supply relationship to help more biopharmaceutical labs access the critical data necessary to close the developability gap.

Rockwell Medical, Inc. announced the publication of results in the Journal of Bioequivalence & Bioavailability from a study designed to investigate the co-administration of intravenous Ferric Pyrophosphate Citrate with unfractionated heparin as an admixture via the HD-machine syringe pump.

AVITA Medical, Inc. announced that its management will present at the following upcoming investor conferences.

DICE Therapeutics, Inc. announced that management will participate in the following investor conferences in November.

Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), today announced the closing of its initial public offering of common stock of 3,520,000 shares at a public offering price of $10.00 per share, for gross proceeds of $35.2 million.

Dante Labs, a global leader in genomics and precision medicine, is pleased to announce its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) reports that recent research analysis provides additional support for anti-oxidation structure/function claims of VINIA®.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today provided a joint business update for the companies and discussed preliminary financial results for the six and nine months ended September 30, 2021.

Alpha Teknova, Inc., a leading provider of critical reagents for the development and production of biopharmaceutical products, including drug therapies, novel vaccines, and molecular diagnostics, announced that the company will participate in the following upcoming investor conferences.